The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis

British Journal of Dermatology

Volumn 170, Issue 4, 2014, Pages 914-921

  Danby, S G ^a   Chittock, J ^a   Brown, K ^a   Albenali, L H ^a,b,c   Cork, M J ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MINISTRY OF HEALTH   (Kuwait)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; PYROGLUTAMIC ACID; TACROLIMUS; TRYPTASE; UROCANIC ACID; CALCINEURIN INHIBITOR; GLUCOCORTICOID; OINTMENT; PEPTIDE HYDROLASE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREAM; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HYDRATION; OINTMENT; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BARRIER; SKIN FUNCTION; SKIN SURFACE; STRATUM CORNEUM; COMPARATIVE STUDY; DERMATITIS, ATOPIC; DRUG EFFECTS; ENZYMOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; SKIN; THERMOREGULATION;

ADMINISTRATION, CUTANEOUS; BETAMETHASONE VALERATE; CALCINEURIN INHIBITORS; DERMATITIS, ATOPIC; GLUCOCORTICOIDS; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; OINTMENTS; PEPTIDE HYDROLASES; SKIN; TACROLIMUS; WATER LOSS, INSENSIBLE;

EID: 84906934808     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12778     Document Type: Article

References (38)

1. Cork MJ, Danby SG, Vasilopoulos Y, et al,. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129: 1892-908.
2. Flohr C, England K, Radulovic S, et al,. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol 2010; 163: 1333-6.
3. Gupta J, Grube E, Ericksen MB, et al,. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008; 121: 725-30.e2.
4. O'Regan GM, Sandilands A, McLean WH, Irvine AD,. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008; 122: 689-93.
5. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
6. Kezic S, O'Regan GM, Yau N, et al,. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy 2011; 66: 934-40.
7. Nemoto-Hasebe I, Akiyama M, Nomura T, et al,. Clinical severity correlates with impaired barrier in filaggrin-related eczema. J Invest Dermatol 2009; 129: 682-9.
8. Reitamo S, Rustin M, Ruzicka T, et al,. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55.
9. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C,. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-28.
10. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ,. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15, quiz 16-18.
11. Svensson A, Chambers C, Gånemo A, Mitchell SA,. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin 2011; 27: 1395-406.
12. Cork MJ, Varghese J, Sultan A, et al,. Therapeutic implications of the differential effects of topical corticosteroids and calcineurin inhibitors on the skin barrier. Presented at the 5th George Rajka International Symposium on Atopic Dermatitis (ISAD), Kyoto, Japan, 11-13 May 2008.
13. Kao JS, Fluhr JW, Man MQ, et al,. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120: 456-64.
14. Williams HC, Burney PG, Pembroke AC, Hay RJ,. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol 1996; 135: 12-17.
15. Danby S, Al Enezi T, Sultan A, et al,. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol 2011; 165: 329-34.
16. Voegeli R, Heiland J, Doppler S, et al,. Efficient and simple quantification of stratum corneum proteins on tape strippings by infrared densitometry. Skin Res Technol 2007; 13: 242-51.
17. Voegeli R, Rawlings AV, Doppler S, et al,. Profiling of serine protease activities in human stratum corneum and detection of a stratum corneum tryptase-like enzyme. Int J Cosmet Sci 2007; 29: 191-200.
18. National Institute for Health and Care Excellence. Atopic eczema in children-guideline consultation. Available at: http://www.nice.org.uk/guidance/ index.jsp?action=folder&r=true&o=34271 (last accessed 20 January 2014).
19. Sheu HM, Lee JY, Chai CY, Kuo KW,. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997; 136: 884-90.
20. Sheu HM, Tai CL, Kuo KW, et al,. Modulation of epidermal terminal differentiation in patients after long-term topical corticosteroids. J Dermatol 1991; 18: 454-64.
21. Aschoff R, Schmitt J, Knuschke P, et al,. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol 2011; 20: 832-6.
22. Cossmann M, Welzel J,. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry: a double-blind, placebo-controlled trial. Br J Dermatol 2006; 155: 700-6.
23. Jensen JM, Pfeiffer S, Witt M, et al,. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 124 (Suppl. 2): R19-28.
24. Shlivko IL, Kamensky VA, Donchenko EV, Agrba P,. Morphological changes in skin of different phototypes under the action of topical corticosteroid therapy and tacrolimus. Skin Res Technol 2013. doi: 10.1111/srt.12095. [Epub ahead of print].
25. Grzanka A, Zebracka-Gala J, Rachowska R, et al,. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012; 21: 184-8.
26. Jensen JM, Scherer A, Wanke C, et al,. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012; 67: 413-23.
27. Howell MD, Kim BE, Gao P, et al,. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120: 150-5.
28. Lloyd D,. Prescription cost analysis-England 2011. Available at: http://www.hscic.gov.uk/catalogue/PUB05807/pres-cost-anal-eng-2011-rep.pdf (last accessed 20 January 2014).
29. Cork MJ, Robinson DA, Vasilopoulos Y, et al,. The effects of topical corticosteroids and pimecrolimus on skin barrier function, gene expression and topical drug penetration in atopic eczema and unaffected controls. J Am Acad Dermatol 2007; 56 (Suppl. 2): AB69.
30. Cork MJ, Varghese J, Hadgraft J, et al,. Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier-implications for therapy. J Invest Dermatol 2007; 127 (Suppl. 1): S45.
31. Demerjian M, Choi EH, Man MQ, et al,. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 2009; 18: 643-9.
32. Rippke F, Schreiner V, Doering T, Maibach HI,. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus aureus. Am J Clin Dermatol 2004; 5: 217-23.
33. Hachem JP, Man MQ, Crumrine D, et al,. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol 2005; 125: 510-20.
34. Morizane S, Yamasaki K, Kabigting FD, Gallo RL,. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol 2010; 130: 1297-306.
35. Briot A, Deraison C, Lacroix M, et al,. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009; 206: 1135-47.
36. Nylander-Lundqvist E, Back O, Egelrud T,. IL-1 beta activation in human epidermis. J Immunol 1996; 157: 1699-704.
37. Komatsu N, Saijoh K, Kuk C, et al,. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol 2007; 16: 513-19.
38. Norris DA,. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005; 53 (Suppl. 1): S17-25.